India drafts instant licence suspension for drugs failing quality tests

India's health ministry wants licences suspended at once when a government lab finds a drug not of standard quality, replacing a show-cause cycle that can take weeks.

By Procupy News DeskPublished 5 Nov 2026, 11:37 AM IST4 min readSource: The Economic Times

In 60 words

India's health ministry has proposed amending the Drugs Rules, 1945 so licensing authorities can suspend a drug's manufacturing licence as soon as a government analyst declares it not of standard quality. A prior show-cause notice would no longer be needed. The licence would stay suspended until the regulator verifies root-cause analysis and corrective action. Comments are open for 30 days.

Key points

A draft dated 28 October would let authorities suspend a drug's manufacturing licence immediately on failures of assay, dissolution, related substances, impurities or sterility^1, 2.
The suspension lifts only after the manufacturer's root-cause analysis and corrective action are verified by the licensing authority^1, 3.
CDSCO and Assam regulators ordered Sun Pharma to stop ophthalmic production at its Assam plant on 20 August, after a show-cause notice⁴.
India supplies around one-fifth of global generic demand and nearly half of US generic prescriptions by volume⁵.

India's health ministry has published draft amendments to the Drugs Rules, 1945^1, 3. They would let regulators suspend a drug's manufacturing licence as soon as a government analyst declares it not of standard quality, without the show-cause notice that current rules require^1, 3. The draft is dated 28 October and the ministry announced it on Wednesday, 4 November^1, 3. Comments are open for 30 days, and the change takes effect when a final notification appears in the Official Gazette^1, 3.

Under the draft, the Central Licensing Approving Authority or a State Licensing Authority could act at once on a government analyst's report². The trigger is a failure on assay, dissolution, related substances, impurities or sterility². Assay measures the amount of active ingredient, and dissolution measures how the drug releases it¹.

Faster action, fewer batches left in circulation

The ministry said the current procedure "may result in a time gap between the declaration of a drug as NSQ and initiation of regulatory action"³. A drug could keep circulating in that gap, making recall harder, it said³. The draft said the listed parameters "are critical to determining the quality of medicines"².

What it takes to restart production

A suspension would last until the manufacturer completes an effective root-cause investigation and puts corrective and preventive action, known as CAPA, in place^1, 2. The ministry said: "Revocation of the suspension shall be permitted only after implementation of the requisite corrective and preventive measures and their due verification by the Licensing Authority"³.

Form 13, the government analyst's test report, would also change³. The report would go at the same time to the Drugs Controller General of India and to the state or union territory licensing authority^1, 3. The manufacturer and the marketer named on the label would receive it too^1, 3.

Scope the draft leaves open

The reported text refers to suspending "the manufacturing licence of the drug", which suggests the licence covering that product rather than the whole plant². The route back described in the reports is verified corrective action, and the reports describe no separate review step^1, 3. The accounts do not say whether marketer or importer licences, or export-only plants, are covered^1, 3.

A recent stop order shows how fast a line halts

On 20 August, two regulators ordered Sun Pharmaceutical Industries to stop manufacturing, selling and distributing ophthalmic products from its Assam plant⁴. The order came from the Central Drugs Standard Control Organisation and the Drugs Controller Assam, documents reviewed by Reuters showed⁴. A joint federal and state inspection found failures in the quality management system⁴. The company had recalled about 11 eye-care brands in July⁴. Regulators issued a show-cause notice on 10 August⁴. They ordered the halt after the response was found unsatisfactory and sought details on 332 recalled batches⁴. Sun Pharma has filed a compliance report that is under review⁴. Ophthalmology is about 3% of its domestic revenue⁴.

How much supply depends on India

Mint put India's pharmaceutical industry at about $60 billion³. India supplies around one-fifth of global generic demand and exports to more than 200 countries, according to Wikipedia's account of the sector⁵. Indian companies supply nearly half of US generic prescriptions by volume and 25% of all medicine in the UK⁵. About 670 manufacturing plants in India are approved by the US Food and Drug Administration⁵. Pharmexcil data show exports of USD 16.13 billion in the first half of the fiscal year, up nearly 5%, with Europe at 20.38% of shipments and Africa up 6.48%⁶.

The proposal follows a run of drug quality scandals. Locally made cough syrups were linked to the deaths of children in India and in Gambia and Uzbekistan^1, 3. Alongside the licence draft, the ministry proposed aligning microbial contamination limits for Grade A clean areas in Schedule M with WHO norms, with the same 30 days for comment³.

What buyers should do now

Check the licence status of each Indian site and product before awarding or renewing a purchase order¹.
Read CDSCO's monthly alerts listing samples declared not of standard quality¹.
Put a notification duty in the contract, so any show-cause notice, adverse inspection finding or stop order is reported within days⁴.
Add a regulatory-action clause that lets the buyer pause orders, require requalification and exit if a licence is suspended^1, 2.
Qualify a second site for single-source Indian SKUs, and hold safety stock where a product has prior NSQ history¹.

What happens next

The ministry has opened the draft for comment for 30 days³. It follows the 65th Drugs Consultative Committee meeting on 20 December 2024 and the 92nd Drugs Technical Advisory Board meeting on 24 April 2025³. Until a final notification, suspensions and cancellations continue to follow the show-cause route^1, 3.

What this means for procurement teams

India's draft rule turns a laboratory finding into a stop-work order, which changes how much protection a purchase order gives a buyer. A licence could be pulled before any show-cause exchange, so the warning period that buyers may have counted on can disappear^1, 2. Where one Indian site supplies a SKU, that gap is the difference between a short delay and a stock-out.

Contract cover matters more than usual. Require suppliers to report any show-cause notice, adverse inspection finding or stop order within days, and add a clause that lets you pause orders, demand requalification and exit without penalty if a licence is suspended⁴. Keep dated evidence of licence status at the point of award.

Before awarding or renewing a purchase order, check licence status and read CDSCO's monthly NSQ alerts¹. Qualify a second site for single-source Indian SKUs and hold safety stock where a product has prior NSQ history. Public buyers can write bidder-eligibility terms and performance security that survive an abrupt suspension.

Cost cuts both ways. Requalifying a site and carrying extra stock add to landed cost, while a stoppage can force spot buys at short notice. India supplies around one-fifth of global generic demand, so spare capacity is limited and qualification queues are long⁵.

Sources

1.BusinessLine, India proposes immediate suspension of drug manufacturing licences over quality failures, 5 November 2026. Accessed 5 November 2026.
2.The Economic Times, Govt plans instant ban on manufacturing of drugs failing key quality tests, 5 November 2026. Accessed 5 November 2026.
3.Mint, Govt proposes immediate licence suspension for substandard drug makers, 4 November 2026. Accessed 5 November 2026.
4.The Economic Times, Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: Report, 30 October 2026. Accessed 5 November 2026.
5.Wikipedia, Pharmaceutical industry in India (Wikipedia), 22 October 2026. Accessed 5 November 2026.
6.The Economic Times, India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil, 29 October 2026. Accessed 5 November 2026.

How this story was made: the Procupy News Desk researched and wrote it with AI tools, working only from the sources listed above. Automated checks confirmed that every number and quote appears in those sources, and a separate AI fact-check compared the story with them before publication. Read our editorial policy. Spotted a mistake? Tell us and we will fix it.